• Profile
Close

A brief communication on circulating PD-1-positive T-regulatory lymphocytes in melanoma patients undergoing adjuvant immunotherapy with nivolumab

Journal of Immunotherapy Aug 16, 2019

Gambichler T, et al. - Since T-regulatory lymphocytes (Tregs) upregulation is known as one of the various immune escape mechanisms of malignancies, researchers investigated how circulating Tregs subpopulations in patients with stage III melanoma are influenced by adjuvant nivolumab during the start of treatment. They found that after the initiation of adjuvant treatment with the PD-1 blocking antibody nivolumab, there was a quick and continuous decrease in circulating PD-1+Tregs. This drop was paralleled with a rise of CTLA-4+Tregs. Findings are suggestive of a possible role of the expression of PD-1 and CTLA-4 on Tregs as a possible biomarker for the effectiveness of immune checkpoint blockade in melanoma.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay